Introduction
Granulocyte transfusions (GTs) from G-CSF-stimulated donors have been shown to increase the absolute neutrophil count (ANC) before expected haematopoietic regeneration in neutropenic patients after chemotherapy or haematopoietic SCT. [1] [2] [3] [4] [5] Thus, GT offers a therapeutic option as treatment adjunct along with antimicrobial agents and growth factors to improve the clinical outcome of patients with severe infections in neutropenia. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, published studies rely on clinical observations of individual cases or series (highest evidence level II-2 or C), and no valid statistical comparison of this treatment method with control groups has been performed. 16, 17 This prospective phase III study aims to compare the efficacy, safety and toxicity of GT in a randomized setting with standard antimicrobial treatment in 74 patients with febrile neutropenia and invasive, life-threatening infections, and to evaluate the possible alteration of incidence and severity of GVHD in 39 allografted patients due to allo-immunization.
Patients and methods
Between 1999 and 2005, seventy-four patients were randomized in 79 infectious episodes in neutropenia to receive antimicrobial treatment according to local standards (broad spectrum antibiotics, antifungals in case of suspected mycosis in a concordant fashion throughout the centres) either with or without administration of GT (X3 times per week; Table 1 ). All patients received G-CSF (30-48 MIU, daily s.c.) continuously during neutropenia and also concomitantly with GT treatment. The mean age was 47 years (range, 14-75 years); the median follow-up time was 401 days. The study was approved by local ethic committees and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from patients and volunteer donors.
Inclusion criteria (i) Haematological malignancy, acquired marrow aplasia or solid tumour, (ii) febrile neutropenia (ANC o0.5 Â 10 6 /l and anticipated duration of aplasia 45 more days) after conventional chemotherapy or haematopoietic SCT, and (iiia) pulmonary infiltrates (except exclusive bronchoalveolar lavage-confirmed detection of virus and interstitial pneumonia) or soft tissue infiltration (45 cm diameter) or (iiib) the history of proven invasive fungal infection according to European Organisation for the Research and Treatment of Cancer and the Mycosis Study Group (EORTC/MSG)-criteria and anticipated duration of neutropenia 410 days. In accordance with an interim study board meeting, a minor proportion of patients was included and randomized in an infectious episode after high-dose chemotherapy already before reaching the nadir of aplasia (with falling levels of ANC, but still above 500 Â 10 6 /l; as indicated in 'Results' and Figure 1) ; these patients were excluded from the calculation of ANC increment and ANC reconstitution after GT.
Exclusion criteria
(i) Adult respiratory distress syndrome, (ii) septic shock or (iii) participation in another investigational drug study.
End points
(i) Survival on day 28 after randomization, (ii) successful treatment of the infection, neutrophil increment, adverse effects, incidence of acute and chronic GVHD.
Donors
Exclusion of viral infections (HIV1/2, HCV, CMV, HbsAg), stimulation with G-CSF (10-17 h (median: 12 h) before apheresis; 5 mg/kg/day ¼ 300-480 mg filgrastim (Neupogen, Amgen, Munich, Germany) or lenograstim (Granocyte, Chugai, Frankfurt, Germany)), leukapheresis with a continous-flow blood cell separator (Spectra, Cobe or CS3000plus, Baxter, Unterschleissheim, Germany) of 7.5 l of blood (range 6-8 l) over 135 min (range 117-180 min) and irradiation of GT (30 Gy) were performed as published. 4, 18 GT was performed within 6 h of apheresis with premedication of prednisolone (1 mg/kg i.v.), antihistamines and antipyretics. The minimum recommended cell content per concentrate was 3 Â 10 8 neutrophils per kg bodyweight. 4 GTs were scheduled every second day. In many centres, no GT Abbrevation: GT ¼ granulocyte transfusions. a Remaining patients with Z500ANC/ml at the time point of randomization showed falling neutrophils after chemotherapy and were expected to undergo a long phase of aplasia. b One patient received an unknown number of GTs, and six received none. c Other diagnoses were as follows: severe aplastic anaemia (n ¼ 2), primitive neuroectodermal tumour (n ¼ 1), paroxysmal nocturnal haemoglobinuria (n ¼ 1), myeloproliferative syndrome (n ¼ 1), secondary AML/MDS (n ¼ 2), non-Hodgkin's lymphomas (n ¼ 6). d One co-infection of Candida plus Aspergillus was detected, and another was probable. # P40.05, not significant.
was performed during weekends for logistic reasons in the departments of transfusion medicine. Administration of GT was discontinued after leukocyte regeneration (that is, white blood cells stably 41.0 Â 10 9 /l 48 h after the previous GT).
Statistics
Survival on day 28 after randomization was chosen as end point indicating successful anti-infectious therapy, because other studied parameters such as duration of fever, elevated C-reactive protein, arterial hypotension and other symptoms of severe infections proved too variable for statistical analyses. The probability to survive 28 days after randomization was estimated to be 60%. The increased survival probability after GT was predicted to be 80% (power). The risk to misinterpret the failure of GT (a-error) is 5%. Considering a drop-out proportion of 10%, the sample size calculation thus resulted in 2 Â 80 patients. The comparison between different subgroups was done with the log-rank test. A P-value of o0.05 was considered significant.
Results and discussion
Ten centres participated in the trial; however, only five recruited patients (n ¼ 74). This corresponds to o50% of the expected sample size. The study was closed prematurely due to a dramatic decrease in the recruitment rate (from 15 in 2001 to 2 in 2005). Discussion during study committee meetings revealed the following main obstacles for participation: (i) patients' and physicians' refusal to randomize in a life-threatening situation, especially if a potentially life-saving strategy (GT) was available, (ii) lack of available donors, (iii) availability of new more effective antimicrobial drugs, for example, linezolid, carbopenems and new antifungal agents such as caspofungin, voriconazole and posaconazole. Patient characteristics were comparable between the randomized cohorts ( Table 1) . Administration of GT was safe, toxicity minimal; only one reversible WHO-grade III pulmonary event (dyspnoea at rest) and one grade III nausea (treatment-requiring vomiting) were observed ( Table 2) . There was no difference in the incidence and severity of GVHD when intervention and control arm were compared, opposing the hypothesis that allo-immunization through third-party neutrophil surface epitopes might yield an increased rate of GVHD after GT. Most episodes included were definite or probable pulmonary or severe soft tissue fungal infections as defined by the international EORTC-MSG criteria (n ¼ 55), and all fulfilled the inclusion criteria. The minority suffered from a bacterial infection or a systemic inflammatory state with unknown pathogen (n ¼ 17; Table 1 ). These proportions differ from general infectious disease statistics on SCT/oncology wards (with predominant bacterial infections) due to the selection required by the GT study's inclusion criteria. The preceding interval from chemotherapy until the randomized infectious episode was clearly documented only in SCT recipients, where a range of 1-22 (median: 2) days passed from SCT date until the first GT administration, and the total duration of preceding episodes of neutropenia was highly variable.
The risk of death during a serious infectious episode as defined by the inclusion criteria decreased during the study period due to the introduction of new antimicrobial agents. Nevertheless, if GT had caused an accelerated neutrophil reconstitution, further therapeutic improvement of the underlying infection could have been expected. In practice, no significant difference in clinical outcome was found whether patients received GT or not ( Table 2 ). The probability of survival on day 28 was 84 and 82% in the GT and the control arm, respectively (intention to treat). No difference in the incidence and causes of death could be identified between the two cohorts. The responses to GT in patients with fungal infections versus bacterial infections might differ due to the underlying immunologic mechanisms of the diseases. Thus, to identify a possible difference in the anti-infective treatment due to GT administration in these subgroups, we analysed patients with proven or probable fungal infections (n ¼ 55 out of 72 episodes, 28 of whom received GT) versus those with bacterial or unidentified pathogens (n ¼ 17 episodes, 10 of whom with GT). Similar to the whole cohort results, the survival on day 28 and until day 100 was independent of GT administration in both subgroups (Table 2) . A minority of patients was randomized at a time when their neutrophil counts were still above 500 Â 10 6 /l because of a qualifying serious invasive infection and rapidly falling ANC with an expected long duration of aplasia (n ¼ 27 of 72 episodes). We did not retrospectively exclude these patients, as an interim study committee meeting decided that these subjects were eligible for evaluation within this study because of comparable inclusion criteria. However, we performed a subanalysis to exclude a potential bias. All calculations of survival on days 28 and 100 in patients with (i) any, (ii) fungal or (iii) bacterial or unknown infections yielded similar results with no detectable effect of GT treatment independent of whether patients had o500 Â 10 6 /l ANC at the time point of randomization or more (Table 2) , suggesting that neutrophil substitution therapy within this study was ineffective even in patients with the most severe neutropenia. Thus, this study failed to identify a target population of patients with a significant benefit from GT administration. Notably, some important observations were made in this trial that might limit the value of any conclusion drawn from the following findings. 9 /l at the time of randomization were monitored for neutrophil increment with or without administration of GT according to the randomization arm. The cumulative incidence of patients with ANC40.5 Â 10 9 /l was plotted against the time (days) after randomization (dotted line: patients randomized to granulocyte transfusion arm (n GT ¼ 27); filled line: patients in the control arm (n no GT ¼ 18)).
First, the ANC reconstitution curves of the treatment and the control arm were congruent (cumulative incidence of patients with ANC4500/ml per group; Figure 1 ), indicating that GT administered at the used schedule and dose were not sufficient to accelerate a lasting peripheral blood neutrophil reconstitution. Directly after GT, we detected an increase of ANC at 1, 8 and 24 h after GT (median: 480, 636 and 493 Â 10 6 /l above pretransfusion Table 2 Results
Clinical course GT No GT P-value
All episodes (n ¼ 72) 28-day survival probability (intention-to-treat analysis), n ¼ episodes 0.84±0.06 n ¼ 38 0.82±0.07 n ¼ 34 NS 28-day survival probability (per protocol analysis), n ¼ episodes 0.81 ± 0.06 n ¼ 38 0.84 ± 0.06 n ¼ 34 NS 100-day survival probability (intention-to-treat) 0.69 ± 0.07 0.72 ± 0.08 NS 100-day-survival probability (per-protocol) 0.67 ± 0.09 0.74 ± 0.08 NS ANCo500/ml at randomization (n ¼ 45) 28-day survival probability (intention-to-treat) 0.77±0.08 (n ¼ 27) 0.76±0.1 (n ¼ 18) NS 28-day survival probability (per-protocol) 0.75 ± 0.08 (n ¼ 28) 0.81 ± 0.1 (n ¼ 17) NS 100-day survival probability (intention-to-treat) 0.65 ± 0.1 0.58 ± 0.12 NS 100-day survival probability (per-protocol) 0.62 ± 0.1 0.61 ± 0.12 NS Episodes with fungal infection (n ¼ 55) 28-day survival probability (intention-to-treat) 0.81±0.07 (n ¼ 27) 0.78±0.08 (n ¼ 28) NS 28-day survival probability (per-protocol) 0.79±0.08 (n ¼ 28) 0.81±0.07 (n ¼ 27) NS 100-day survival probability (intention-to-treat) 0.66 ± 0.09 0.71 ± 0.09 NS 100-day survival probability (per-protocol) 0.63 ± 0.09 0.74 ± 0.09 NS Episodes with bacterial or unknown infection (n ¼ 17) 28-day survival probability (intention-to-treat) 0.90±0.09 (n ¼ 11) 1 (n ¼ 6) NS 28-day survival probability (per-protocol) 0.90±0.09 (n ¼ 10) 1 (n ¼ 7) NS 100-day survival probability (intention-to-treat) 0.79 ± 0.13 0.75 ± 0.22 NS 100-day survival probability (per-protocol) 0.79 ± 0.13 0.75 ± 0.
NS
Episodes with fungal infection and ANCo500/ml at randomization (n ¼ 33) 28-day survival probability (intention-to-treat) 0.74±0.1 (n ¼ 19) 0.71±0.12 (n ¼ 14) NS 28-day survival probability (per-protocol) 0.70±0.1 (n ¼ 20) 0.77±0.12 (n ¼ 13) NS 100-day survival probability (intention-to-treat) 0.62±0.11 0.57±0.13 NS 100-day survival probability (per-protocol) 0.59 ± 0.11 0.62 ± 0.13 NS Episodes with bacterial or unknown infection and ANCo500/ml at randomization (n ¼ 12) 28-day survival probability (intention-to-treat) 0.88±0.12 (n ¼ 8) Abbrevation: GT ¼ granulocyte transfusions. a Three patients, although randomized to 'no GT', received total of six courses of GT. b Proportion of episodes treated with less than three GT: 16/33, 1/6, 17/39, respectively. c Including one episode of GT also suffering from an adverse effect (see above). # P40.05, not significant. levels, respectively; data not shown) with few exceptionally high increments (maximum: 7200, 5700 and 5700 Â 10 6 /l neutrophils at 1, 8 and 24 h after GT, respectively). However, these high increments were randomly distributed among recipients and episodes and only rarely correlated to the cell dose in the transfusions (that is, upper-quartile ANC increments did not correspond to the neutrophilrichest concentrates and vice versa; data not shown). Similarly, the variability of GT cell content (median neutrophils 6.6 Â 10 8 /kg/concentrate, range 1.2-16, indicating that about 16% of GT contained less than the minimum recommended neutrophil dose of 3 Â 10 8 per kg bodyweight) was evenly distributed between the GT recipients/episodes and thus did not cause a detectably different outcome of individuals. In contrast to previous observations, the response of GT in patients in whom GT were given early (o4 days) was equal to that of GT given Z4 days after infection diagnosis and randomization (range 1-14 days, median ¼ 4). Thus, there was neither survival benefit from a short duration between randomization and GT administration, nor any disadvantage from a prolonged interval (see below). Furthermore, the relatively long median time lag from randomization to first GT of 4 days and the administration schedule (thrice a week instead of daily) did not allow rapid and durable restoration of the neutrophil count. Studies in severely life-threatening infectious episodes in children and adults clearly showed a correlation between transfused cell number, early GT administration and effect on ANC increment and survival. 4, 5, 14, 19 Some collection facilities could not process GT during weekends. Yet, prepared concentrates were administered to the corresponding patients, even if the cell content or timing were not satisfactory. Additionally, there was no difference in the neutrophil response to the first or subsequent GT in any single recipient, suggesting that antineutrophil immunization of the recipient did not occur or was not clinically relevant. Concomitant cytokine therapy in addition to G-CSF to enhance the function of transfused neutrophils, such as recombinant IFN-g1b, has shown promising results, [20] [21] [22] but detection or pharmacological stimulation of neutrophil function were not part of this study, which relied on neutrophil counts and clinical performance parameters. Peripheral blood counts might be an inadequate surrogate marker to assess the efficacy of GT because neutrophil tissue infiltration at the site of infection precedes the peripheral blood ANC increment. Mucosal neutrophil counts obtained by oral lavage have been shown to correlate better to tissue granulocyte concentrations than ANC, 23 but they were not available within this study. Secondly, another explanation for the better-thanestimated outcome of both cohorts and the failure of this study to detect an improved survival after granulocyte support for infections in neutropenia could be a 'healthy cohort' bias due to inclusion of patients not requiring GT and thus not expected to profit from this measure. Although all patients were severely ill as defined by meeting the inclusion criteria, it remained unclear why many patients recovered from their infectious episodes after only one or two GT (Table 2) . Of note, 17 of 39 GT-receiving patients (44%) received only 1-2 GTs before neutrophil recovery and thus discontinuation of GT treatment (median number: 3 GTs, range 1-13; median duration of GT administration: 6 days, range , suggesting that the potentially detectable effect of granulocyte support in a majority of subjects was minimal. It appears unlikely that the administration of only 1-2 GTs represented the key to rapidly resolve a life-threatening infection justifying immediate discontinuation of GT treatment. Potentially, a lower level of neutropenia at randomization than 500 Â 10 6 / l ANC (for example, at ANCo200 Â 10 6 /l) as inclusion criterion would have facilitated detection of an improved clinical outcome after GT treatment. However, the ANC level for inclusion of patients was not intended to represent the nadir of neutropenia but to allow an early intervention in life-threatening infections even before the patients underwent the deepest phase of anticipated aplasia. Six patients, who did not receive GT although randomized to the treatment arm, and subjects with prolonged time lag (47 days, n ¼ 7) from randomization to their first administration of GT, performed equally with respect to survival from severe infections, such as those who received GT within 7 days after randomization.
Thirdly, it was noted that numerous GTs were performed in the observation period without randomization in centres that planned to participate but did not randomize any patients. Three patients received six episodes of GT because of their deteriorating clinical state although randomized to the control arm, indicating that the existing empirical evidence for the benefit of this therapeutic measure was sufficient for the responsible physicians (Table 2) , as if these subjects were not eligible for randomization according to the uncertainty principle. 24 However, because it is not statistically correct to exclude patients retrospectively from a randomized study, we calculated the effect of GT for all identified subgroups of patients (intention-to-treat, perprotocol, ANCo500 Â 10 6 /l at randomization, fungal or bacterial infections and so on) to rule out a bias in the interpretation of results.
In summary, these data fail to confirm or refute the benefit of GT treatment because (i) the patient population in which this randomized clinical study was performed recovered faster than expected even without GT, and (ii) the transfused cumulative granulocyte doses and GT interval density in this trial were inefficient according to previous own and published experience. 4, 10, 14, 16, 17, 19, [25] [26] [27] This study raises issues about the ethical feasibility of randomization of a safe and potentially life-saving treatment with level II-2 (or C) evidence of efficacy, points out future technical and clinical challenges, as well as recommendations for a still missing valid randomized controlled trial to obtain level I (A) evidence of the efficacy of GT treatment:
(1) The observed delay and the slow sequence of GT administration could be circumvented in a future study by randomizing patients and identifying potential family donors already before administration of chemotherapy and scheduling daily aphereses once GT treatment is commenced. (2) To detect a difference in the clinical outcome with or without GT therapy, a selection of a homogenous cohort with even higher risk to succumb to a lifethreatening infection during neutropenia, such as patients with refractory AMLs with prolonged preceding phases of neutropenia and ANCo200 Â 10 6
/l, appears to be essential. (3) In a future trial, all generated and handed out GT should be reported by the departments of transfusion medicine to avoid an undetected bypass of GT for notincluded recipients during the study period, even if randomization is neglected by the patient or physician.
